NEOPLASMS BY SITE
Clinical trials for NEOPLASMS BY SITE explained in plain language.
Never miss a new study
Get alerted when new NEOPLASMS BY SITE trials appear
Sign up with your email to follow new studies for NEOPLASMS BY SITE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted pill shows promise for rare lung cancer, but trial stopped early
Disease control TerminatedThis phase 3 study tested a new drug called pralsetinib against standard chemotherapy for people with a specific type of advanced lung cancer that has a RET gene fusion. The goal was to see if pralsetinib could better delay cancer growth. The trial was terminated early, so full r…
Matched conditions: NEOPLASMS BY SITE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New targeted drug shows promise for Hard-to-Treat stomach cancers
Disease control TerminatedThis early-phase trial tested a new drug called EO-3021, which targets a protein (CLDN18.2) found on some cancer cells. The study included 88 adults with advanced stomach or gastrointestinal cancers that had not responded to standard treatments. Participants received EO-3021 alon…
Matched conditions: NEOPLASMS BY SITE
Phase: PHASE1 • Sponsor: Elevation Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Kidney cancer combo trial halted early – what we know
Disease control TerminatedThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …
Matched conditions: NEOPLASMS BY SITE
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC